W.G. Shaheen & Associates DBA Whitney & Co Has $10.53 Million Stake in Stryker Co. (NYSE:SYK)

W.G. Shaheen & Associates DBA Whitney & Co increased its position in Stryker Co. (NYSE:SYK) by 1.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 29,240 shares of the medical technology company’s stock after buying an additional 519 shares during the period. W.G. Shaheen & Associates DBA Whitney & Co’s holdings in Stryker were worth $10,528,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SYK. Edge Capital Group LLC lifted its position in Stryker by 7.1% in the fourth quarter. Edge Capital Group LLC now owns 1,144 shares of the medical technology company’s stock worth $412,000 after purchasing an additional 76 shares during the period. IFP Advisors Inc lifted its position in shares of Stryker by 43.7% during the fourth quarter. IFP Advisors Inc now owns 2,239 shares of the medical technology company’s stock worth $808,000 after purchasing an additional 681 shares in the last quarter. J. W. Coons Advisors LLC grew its stake in shares of Stryker by 0.7% during the fourth quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company’s stock valued at $1,315,000 after purchasing an additional 26 shares during the last quarter. Waverton Investment Management Ltd increased its holdings in shares of Stryker by 10.2% in the fourth quarter. Waverton Investment Management Ltd now owns 1,369 shares of the medical technology company’s stock valued at $493,000 after purchasing an additional 127 shares in the last quarter. Finally, HealthInvest Partners AB raised its position in Stryker by 9.4% in the 4th quarter. HealthInvest Partners AB now owns 25,660 shares of the medical technology company’s stock worth $9,296,000 after purchasing an additional 2,200 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Shares of NYSE SYK opened at $382.59 on Monday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The stock has a 50 day moving average price of $378.07 and a 200 day moving average price of $369.34. The stock has a market capitalization of $145.99 billion, a PE ratio of 49.30, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the business earned $3.46 EPS. Analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Wall Street Analyst Weigh In

SYK has been the subject of several research reports. Canaccord Genuity Group lifted their target price on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. The Goldman Sachs Group boosted their price objective on Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a report on Thursday, January 30th. Evercore ISI raised their target price on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Argus set a $450.00 price target on shares of Stryker in a research note on Monday, February 3rd. Finally, BTIG Research raised their price objective on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $422.15.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.